Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 557 results for women's health

  1. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  2. NICE recommends offering PrEP to people at high risk of HIV for first time

    People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the first time.

  3. NICE recommends several treatment options to help with rheumatoid arthritis

    Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.

  4. NICE recommends treatment options for severe pregnancy sickness

    Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptom.

  5. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

  6. NICE recommends innovative treatment for severe blood disorder for NHS use

    Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.

  7. Women should be offered induced labour earlier than previously advised

    Induced labour should be offered earlier than previously advised to make birth safer for women and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.

  8. Make your voice heard on a NICE committee

    Kendall who is a GP and sits on NICE committees producing guidelines on women's health. They discuss the vital role of our independent...

  9. Our updated guideline to improve the diagnosis of endometriosis

    The guideline makes new recommendations and updates existing ones on diagnosing and managing a condition that affects approximately 1.5 million women of reproductive age in the UK.

  10. Updated menopause guidance includes discussion aid to support conversations about HRT

    Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.

  11. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  12. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

  13. Updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  14. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  15. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer